The market for diagnostic products, both as pre-assembled kits and for use in clinical laboratories, is growing very rapidly. This growth reflects the accelerated rate at which genomics and proteomics efforts, supported by the mapping of the human genome, are identifying new genes and proteins that are markers for human disease or that predict responsiveness to particular new drugs. The current diagnostics market is characterized by high margins and shorter product approval time lines than for biopharmaceuticals, and is expected to grow to a multi-billion dollar size within the next decade.

In parallel with the growth in the diagnostic products market, there is a burgeoning need for the purified proteins, antibodies, and other reagents that are used in these products. Development of a diagnostic assay involves the identification, characterization, and production of highly selective biological molecules that uniquely interact with specific targets. These targets include diseased cells, antigens, pathogens, hormones, or chemicals produced by the human body or invading microorganisms. A variety of recombinant proteins and enzymes, such as peroxidases, alkaline phosphatases, kinases, nuclear receptors, and drug metabolizing enzymes are already being used for diagnostic purposes.

In collaboration with others, Dyadic intends to utilize its integrated C1 technology platform to rapidly, and cost-effectively, discover and develop new diagnostic products and technologies. Dyadic’s hyper-producing C1 protein expression system (More at Gene Expression) is capable of discovering, developing, scaling up and producing commercial quantities of the proteins, enzymes, antibodies and peptides used in diagnostic products.

Another use of Dyadic’s C1 technology platform is to produce reagents for basic research and pharmaceutical product development. In addition, the food and agricultural products industry is developing diagnostic kits to detect meat and produce spoilage at an early stage by using enzymes, which can save billions of dollars of waste and improve human health. Dyadic can also supply protein reagents for these uses.

Dyadic is interested in strategic business relationships with companies worldwide to help discover, develop and manufacture novel diagnostic products. Dyadic’s C1 technology platform and scale up and manufacturing expertise can assist those companies in such efforts.

Whether your business needs milligram, gram or kilogram quantities, think of Dyadic as your “One Stop Shop” (View Diagram) for recombinant proteins, enzymes, peptides, antibodies and other diagnostic reagents.